7th Apr 2014 17:41
NOTIFICATION OF TRANSACTIONS OF DIRECTORS AND APPLICABLE EMPLOYEE
VERNALIS PLC (the "Company")
7 April 2014
Vernalis plc (LSE: VER) announces today, in accordance with the rules of the 2012 Value Builder Plan, the following options over the Company's ordinary shares, with a nominal value of 1 pence each, were granted today to the Executive Directors and a member of the management committee (who is an "Applicable Employee" for the purposes of the AIM Rules for Companies):
Executive Director | No of shares under option | Exercise Price | % of Issued Share Capital |
Ian Garland | 2,070,608 | 1 pence | 0.47% |
David Mackney | 1,441,984 | 1 pence | 0.33% |
Applicable Employee | No of shares under option | Exercise Price | % of Issued Share Capital |
Mike Wood | 404,852 | 1 pence | 0.09% |
The options are exercisable five years following grant provided that the performance conditions of the option scheme are met.
Enquiries:
Vernalis | +44 (0) 118 938 0015 |
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
| |
Canaccord Genuity Limited (Nominated Adviser): | +44 (0) 20 7523 8350 |
Lucy Tilley Dr Julian Feneley Henry Fitzgerald-O'Connor
| |
Shore Capital (Joint Broker) | +44 (0)20 7408 4090 |
Bidhi Bhoma Toby Gibbs
| |
Brunswick Group | +44 (0) 20 7404 5959 |
Jon Coles
|
Notes to Editors
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit www.vernalis.com
Related Shares:
Vernalis PLC